November 2, 2021

Precision BioLogic is pleased to expand our family of factor deficient plasmas with the launch of our new CRYOcheck™ Factor VIII Deficient Plasma with VWF in Canada, the European Union, Australia, and New Zealand. The launch follows market authorization by Health Canada and respective in-country regulatory authorities.

Intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A, CRYOcheck Factor VIII Deficient Plasma with VWF has normal levels of VWF and FVIII antigen levels of less than 1%. The importance of FVIII antigen levels in the performance of FVIII deficient substrates was recently demonstrated in a study presented at ISTH 2021¹.

CRYOcheck Factor VIII Deficient Plasma with VWF comes in a convenient frozen format, which eliminates reconstitution errors and reduces preparation time. It is manufactured from platelet-poor plasma, which is immunodepleted and assayed at less than 1% FVIII activity by functional and antigenic methods. Purified VWF is reintroduced, and the plasma is buffered and frozen. VWF activity and antigen levels are available for every lot.

Learn more about the features and benefits of CRYOcheck Factor VIII Deficient Plasma with VWF.

 

¹A. Wood, N. Kesavan, A. Sadeghi-Khomami, K. Black, M. Boylan, R. Ni, J. Della Maestra, P. Erb, D. Foulon, H. Hoogendoorn; ISTH 2021; The Impact of Inactive FVIII Antigen in Factor VIII Deficient Plasma on the Measurement of FVIII Inhibitors.